Nektar Therapeutics filings document the regulatory record of a Delaware clinical-stage biotechnology issuer with common stock listed on the Nasdaq Capital Market under NKTR. The company's 8-K reports cover financial results, Regulation FD clinical disclosures for rezpegaldesleukin, material definitive agreements, underwriting arrangements, at-the-market equity distribution mechanics, and shelf-registration-related offerings.
Proxy materials describe annual meeting matters, director elections, equity incentive plan authorization, auditor ratification, executive compensation votes, and governance procedures. Nektar's filing record also reflects capital-structure disclosures for common stock and pre-funded warrants, clinical-stage pipeline risks, research and development funding needs, and public-company controls tied to its immunology drug development business.
Nektar Therapeutics (NKTR) reported Phase 2b results for rezpegaldesleukin in alopecia areata and atopic dermatitis, including follow-up after treatment ended. In REZOLVE-AA, SALT Score ≤20 responses were maintained in 75% of patients four months off treatment and 63% at six months. SALT Score ≤10 was reached by 19% at six months off treatment, compared with 7% at Week 52.
In REZOLVE-AD, Nektar reported new and sustained responses across EASI-75, vIGA-AD 0/1 and Itch NRS with monthly and quarterly maintenance dosing; some patients achieved EASI-100. Nektar described safety through 52 weeks in both studies as favorable and consistent with previously reported profiles. A third Phase 3 atopic dermatitis study in patients with prior systemic biologic and/or JAK inhibitor experience has started. The 850-patient Phase 3 alopecia areata study is planned to begin in early 2027.
Nektar Therapeutics (NKTR) is the issuer in a Schedule 13G/A in which Two Seas Capital LP, Two Seas Capital GP LLC and Sina Toussi report the same beneficial-ownership position: 3,345,978 common shares, or 9.8%. The shares are held by Two Seas Global (Master) Fund LP (3,175,430 shares) and Two Seas Litigation Opportunities Fund LLC (170,548 shares).
The reporting persons report sole voting and dispositive power over 3,345,978 shares and shared power over none. The 9.8% figure is calculated using 34,142,994 common shares outstanding as of August 7, 2026. Sina Toussi is identified as Two Seas Capital’s chief investment officer and the managing member of Two Seas Capital GP.
NEKTAR THERAPEUTICS director Roy A. Whitfield received a 2,000-share restricted stock unit award and a stock option grant covering 4,000 shares on September 23, 2026. The RSUs vest in full one year following that date; the options vest in substantially equal monthly installments over the one-year period beginning that date, have a $57.66 exercise price and expire September 22, 2034. His reported direct common-stock holdings after the transactions were 16,417 shares. Reported indirect holdings were 3,434 shares by the Whitfield Family 2020 Trust and 1,334 shares by Family Trust. No Rule 10b5-1 plan is reported for the transactions.
NEKTAR THERAPEUTICS director Greer R. Scott received grants of 2,000 restricted stock units (RSUs) and 4,000 stock options on September 23, 2026. The RSUs vest in full one year following September 23, 2026; the options vest in substantially equal monthly installments over the one-year period beginning September 23, 2026, have a $57.66 exercise price and expire September 22, 2034. The reported security amounts reflect the one-for-fifteen reverse stock split effected on June 8, 2025.
Nektar Therapeutics director Robert Chess received grants of 2,000 restricted stock units and 4,000 stock options on September 23, 2026. His direct common-stock holdings following the RSU award were 19,019 shares. Each RSU represents a contingent right to receive one common share upon vesting, and the award vests in full one year following September 23, 2026.
The options have a $57.66 exercise price, vest in substantially equal monthly installments over the one-year period beginning September 23, 2026, and expire September 22, 2034. The report also lists 140 shares held by his son; Chess disclaims beneficial ownership of those shares. No Rule 10b5-1 plan is reported.
NEKTAR THERAPEUTICS director Diana Brainard reported two equity awards on September 23, 2026: 2,000 restricted stock units (RSUs), representing contingent rights to common shares, and options for 4,000 common shares. The RSUs vest in full one year following September 23, 2026; the options vest in substantially equal monthly installments over the one-year period beginning on September 23, 2026, at a $57.66 exercise price, and expire September 22, 2034. Her reported direct common-stock holdings after the RSU award were 3,904 shares; the reported post-award amount for the options was 4,000. No Rule 10b5-1 plan is reported.
NEKTAR THERAPEUTICS director Jeffrey Robert Ajer received 2,000 restricted stock units and an option covering 4,000 common shares on September 23, 2026. The reported direct common-stock position following the RSU award was 4,277 shares. Each RSU represents a contingent right to one common share upon vesting.
The RSUs vest in full one year following September 23, 2026; the option vests in substantially equal monthly installments over the one-year period beginning that date. The option has a $57.66 per-share exercise price and expires September 22, 2034. The reported securities amounts reflect the one-for-fifteen reverse stock split effected June 8, 2025.
Nektar Therapeutics (NKTR) announced that it is entering a quiet period starting September 8, 2026, which will continue until the public announcement of data from the 24-week off-treatment follow-up period of its Phase 2b REZOLVE-AA study of rezpegaldesleukin in patients with severe-to-very-severe alopecia areata.
The company states that this quiet period is consistent with its prior quiet periods for Phase 2b REZOLVE studies and planned data disclosures, and the information is furnished under Regulation FD rather than filed.
NEKTAR THERAPEUTICS (NKTR) reported that Chief R&D Officer Jonathan Zalevsky sold 186 shares of common stock on August 18, 2026 at a weighted-average price of $71.98 per share. The sale was made solely to cover required tax withholding upon RSU vesting and is not a discretionary trade. After this sale, he holds 9,570 shares of NKTR common stock directly.